Skip to main content

The United States Food and Drug Administration (FDA) has approved Genentech’s agent Avastin (bevacizumab) for the treatment of advanced breast cancer. Specifically, the indications include Avastin, in combination with Taxol® (paclitaxel) for patients with metastatic human epidermal receptor 2-negative (HER2-negative) breast cancer who have not received prior chemotherapy for metastatic disease.

The somewhat surprising approval comes following the ODAC recommendation for rejection of this indication.

The approval was prompted by an improvement in progression-free survival of 5.5 months with Avastin/Taxol over Taxol alone, with no demonstration of a survival improvement with Avastin.

Avastin is already approved for colon and lung cancer.

Recommended Articles

shutterstock_1827224507

Treatment of Stage IV Cervical Cancer

Immunotherapy and precision cancer medicines take the lead for treatment of advanced cervical cancer.

shutterstock_1827224507

Treatment of stage II cervical cancer may include surgery, radiation, chemotherapy or precision cancer medicines.

Treatment of stage II cervical cancer may include surgery, radiation, chemotherapy or precision cancer medicines.

veggies

Nutritional Needs during Cancer Treatment

Expert insight into eating well during cancer treatment